Guillain-Barre Syndrome Developing During Infliximab Treatment for Psoriatic Arthritis: A Case Report
Yıl: 2016 Cilt: 7 Sayı: 1 Sayfa Aralığı: 117 - 119 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022
Guillain-Barre Syndrome Developing During Infliximab Treatment for Psoriatic Arthritis: A Case Report
Öz: Tümör nekroz faktörü (TNF)-?, immun sisteminin gelişimi, immün yanıtın düzenlenmesi ve T- hücre aracılı dokusal olaylarda birçok açıdan önemli rol oynar. Otoreaktif T-hücreleri ve makrofajlar tarafından salınan TNF-?' nın immün demiyelinizan nöropatilerin patogenezinde rol oynayabileceğine dair kanıtlar gözlenmiştir. Demiyelinizan nöropatiler anti TNF- ? tedavisinin nadir yan etkilerindendir. Demiyelinizan nöropatilerin konvansiyonel tedavisiyle ve kullanılan ilaçların kesilmesi ile sıklıkla tablo geriler. Bu yazıda anti TNF-? (infliksimab) tedavisi sonrasında demiyelinizan nöropati kliniği gelişen bir hastanın sunulması amaçlanmıştır. Bu olguda Guillan Barre Sendromu Anti TNF tedavisine sekonder olarak gelişmektedir. Anti TNF- ? tedavisinin devamının, nöropatinin uzun vadedeki seyrine etkisi net değildir. Tedavinin kesilmesi her zaman nöropati kontrolü için gerekli olmayabilir. Ancak bizim olgumuzda olduğu gibi Anti TNF- ? tedavisiyle ilişkili gelişen bir Guillian Barre sendromu tablosunda tedavi sonlandırılabilir.
Anahtar Kelime: Konular:
Psöriatik Artritli Bir Hastada İnfliksimab Tedavisi Sırasında Gelişen Guillain-Barre Sendromu: Olgu Sunumu
Öz: Tumor necrosis factor (TNF)-? plays an important role in many aspects of immune system development, immune-response regulation, and T-cell-mediated tissue injury. The evidence that TNF-?, released by auto reactive T cells and macrophages, may contribute to the pathogenesis of immune-mediated demyelinating neuropathies is reviewed. Demyelinating neuropathies are rare adverse events of anti-TNF-? therapy. Improvement usually occurs after drug interruption and/or in association with conventional treatments for demyelinating neuropathies. We aimed to report a patient with demyelinating neuropathy occurring after TNF blocker (infliximab) treatment. The development of Guillain-Barre syndrome in this report may have been secondary to anti-TNF-? treatment. The influence of antiTNF-? treatment continuation on the long-term course of neuropathy is variable, suggesting that anti-TNF-? treatment withdrawal is not always necessary for neuropathy control. But such as the report, anti-TNF-? treatment may be stopped.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Olgu Sunumu Erişim Türü: Erişime Açık
- Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism. Arthritis Rheum 2001;44:1977-83.
- Emmungil E, Aksu K. Anti-tumor necrosis factor alpha related autoimmune and inflammatory diseases. RAED Journal 2012; 4(1):17-23.
- Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. De- myelination occurring during anti-tumor necrosis factor alpha therapy for inflam- matory arthritides, Arthritis Rheum 2001;44:2862-9.
- Shin I-S J, Baer AN, Kwon HJ, Papadopoulos EJ, Siegel JN. Guillain-Barre´ and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum 2006;54:1429-1434.
- Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-alpha in autoimmune disease. Proc Natl Acad Sci USA 2005;102:3372-7.
- Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL et al.; British Society for Rheumatology Biologics Register Control Centre Consortium; BSRBR. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti- tumour necrosis factor alpha therapy: results from the British Society for Rheuma- tology Biologics Register. Ann Rheum Dis 2009;68:209-15.
- Stübgen JP. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve 2008;37:281-92.
- Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases in- duced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007;86:242-51.
| APA | TÜFEKÇİ O, karahan a, YEŞİLYURT S (2016). Guillain-Barre Syndrome Developing During Infliximab Treatment for Psoriatic Arthritis: A Case Report. , 117 - 119. |
| Chicago | TÜFEKÇİ Osman,karahan ali yavuz,YEŞİLYURT Selçuk Guillain-Barre Syndrome Developing During Infliximab Treatment for Psoriatic Arthritis: A Case Report. (2016): 117 - 119. |
| MLA | TÜFEKÇİ Osman,karahan ali yavuz,YEŞİLYURT Selçuk Guillain-Barre Syndrome Developing During Infliximab Treatment for Psoriatic Arthritis: A Case Report. , 2016, ss.117 - 119. |
| AMA | TÜFEKÇİ O,karahan a,YEŞİLYURT S Guillain-Barre Syndrome Developing During Infliximab Treatment for Psoriatic Arthritis: A Case Report. . 2016; 117 - 119. |
| Vancouver | TÜFEKÇİ O,karahan a,YEŞİLYURT S Guillain-Barre Syndrome Developing During Infliximab Treatment for Psoriatic Arthritis: A Case Report. . 2016; 117 - 119. |
| IEEE | TÜFEKÇİ O,karahan a,YEŞİLYURT S "Guillain-Barre Syndrome Developing During Infliximab Treatment for Psoriatic Arthritis: A Case Report." , ss.117 - 119, 2016. |
| ISNAD | TÜFEKÇİ, Osman vd. "Guillain-Barre Syndrome Developing During Infliximab Treatment for Psoriatic Arthritis: A Case Report". (2016), 117-119. |
| APA | TÜFEKÇİ O, karahan a, YEŞİLYURT S (2016). Guillain-Barre Syndrome Developing During Infliximab Treatment for Psoriatic Arthritis: A Case Report. Journal of Clinical and Analytical Medicine, 7(1), 117 - 119. |
| Chicago | TÜFEKÇİ Osman,karahan ali yavuz,YEŞİLYURT Selçuk Guillain-Barre Syndrome Developing During Infliximab Treatment for Psoriatic Arthritis: A Case Report. Journal of Clinical and Analytical Medicine 7, no.1 (2016): 117 - 119. |
| MLA | TÜFEKÇİ Osman,karahan ali yavuz,YEŞİLYURT Selçuk Guillain-Barre Syndrome Developing During Infliximab Treatment for Psoriatic Arthritis: A Case Report. Journal of Clinical and Analytical Medicine, vol.7, no.1, 2016, ss.117 - 119. |
| AMA | TÜFEKÇİ O,karahan a,YEŞİLYURT S Guillain-Barre Syndrome Developing During Infliximab Treatment for Psoriatic Arthritis: A Case Report. Journal of Clinical and Analytical Medicine. 2016; 7(1): 117 - 119. |
| Vancouver | TÜFEKÇİ O,karahan a,YEŞİLYURT S Guillain-Barre Syndrome Developing During Infliximab Treatment for Psoriatic Arthritis: A Case Report. Journal of Clinical and Analytical Medicine. 2016; 7(1): 117 - 119. |
| IEEE | TÜFEKÇİ O,karahan a,YEŞİLYURT S "Guillain-Barre Syndrome Developing During Infliximab Treatment for Psoriatic Arthritis: A Case Report." Journal of Clinical and Analytical Medicine, 7, ss.117 - 119, 2016. |
| ISNAD | TÜFEKÇİ, Osman vd. "Guillain-Barre Syndrome Developing During Infliximab Treatment for Psoriatic Arthritis: A Case Report". Journal of Clinical and Analytical Medicine 7/1 (2016), 117-119. |
